Natera launches Zenith whole genome sequencing test for rare disease diagnosis

Reuters03-12
Natera launches Zenith whole genome sequencing test for rare disease diagnosis
  • Commercial launch announced for Zenith genomics, a whole genome sequencing assay for rare disease diagnosis.
  • Rare diseases were cited as affecting an estimated 30 million Americans annually, with average diagnostic journeys of 4-7 years.
  • The U.S. economic burden of rare diseases in 2019 was cited at nearly USD 997 billion, including USD 449 billion in direct medical costs.
  • Indirect and non-medical costs were cited at USD 548 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260312908723) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment